These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 19851515)
1. Asenapine monotherapy in the acute treatment of both schizophrenia and bipolar I disorder. Bishara D; Taylor D Neuropsychiatr Dis Treat; 2009; 5():483-90. PubMed ID: 19851515 [TBL] [Abstract][Full Text] [Related]
2. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Citrome L Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150 [TBL] [Abstract][Full Text] [Related]
3. Asenapine: a review of acute and extension phase data in bipolar disorder. McIntyre RS CNS Neurosci Ther; 2011 Dec; 17(6):645-8. PubMed ID: 20950326 [TBL] [Abstract][Full Text] [Related]
4. Receptor mechanisms of antipsychotic drug action in bipolar disorder - focus on asenapine. Reynolds GP Ther Adv Psychopharmacol; 2011 Dec; 1(6):197-204. PubMed ID: 23983947 [TBL] [Abstract][Full Text] [Related]
6. Asenapine: a clinical review of a second-generation antipsychotic. Stoner SC; Pace HA Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521 [TBL] [Abstract][Full Text] [Related]
7. Current Trends on Antipsychotics: Focus on Asenapine. Marazziti D; Piccinni A; Baroni S; Mungai F; Presta S; Mucci F; Dell'Osso L Curr Med Chem; 2016; 23(21):2204-16. PubMed ID: 27222264 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical efficacy of asenapine in schizophrenia. Minassian A; Young JW Expert Opin Pharmacother; 2010 Aug; 11(12):2107-15. PubMed ID: 20642375 [TBL] [Abstract][Full Text] [Related]
11. Asenapine: a synthesis of efficacy data in bipolar mania and schizophrenia. McIntyre RS; Wong R Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):217-20. PubMed ID: 22182459 [TBL] [Abstract][Full Text] [Related]
12. Pharmacology and efficacy of asenapine for manic and mixed states in adults with bipolar disorder. McIntyre RS Expert Rev Neurother; 2010 May; 10(5):645-9. PubMed ID: 20420486 [TBL] [Abstract][Full Text] [Related]
13. Asenapine: A Review in Schizophrenia. Plosker GL; Deeks ED CNS Drugs; 2016 Jul; 30(7):655-66. PubMed ID: 27356921 [TBL] [Abstract][Full Text] [Related]
14. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Gao K; Mackle M; Cazorla P; Zhao J; Szegedi A Neuropsychiatr Dis Treat; 2013; 9():1145-57. PubMed ID: 24003306 [TBL] [Abstract][Full Text] [Related]
15. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Bishara D; Taylor D Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393 [TBL] [Abstract][Full Text] [Related]
16. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Swainston Harrison T; Perry CM Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633 [TBL] [Abstract][Full Text] [Related]
17. Asenapine Treatment in Pediatric Patients with Bipolar I Disorder or Schizophrenia: A Review. Stepanova E; Grant B; Findling RL Paediatr Drugs; 2018 Apr; 20(2):121-134. PubMed ID: 29170943 [TBL] [Abstract][Full Text] [Related]
19. Role of sublingual asenapine in treatment of schizophrenia. Citrome L Neuropsychiatr Dis Treat; 2011; 7():325-39. PubMed ID: 21655346 [TBL] [Abstract][Full Text] [Related]
20. Asenapine in bipolar I disorder: evidence and place in patient management. Samalin L; Charpeaud T; Llorca PM Ther Adv Chronic Dis; 2013 Jan; 4(1):5-14. PubMed ID: 23342243 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]